GLP-1s and Their Impact on Health Insurance

In recent years, a new class of medications has transformed the conversation around weight management, diabetes, and chronic disease. Known as GLP-1 receptor agonists, drugs like Ozempic, Wegovy, and Zepbound are showing impressive results for patients—but they are also reshaping the health insurance landscape for employers and employees alike.

For business owners and HR leaders, the growing popularity of GLP-1 medications raises an important question: What does this mean for the cost and structure of employer health plans?

At Haughn Insurance in Dublin, Ohio, we help employers understand trends like this and make informed decisions about their benefits strategy.

What Are GLP-1 Medications?

GLP-1 medications were originally developed to treat Type 2 diabetes, but they are now widely used to treat obesity and support significant weight loss. These medications work by mimicking a hormone that regulates blood sugar and appetite, helping patients feel fuller longer and improving insulin response.

Because obesity and metabolic disease affect millions of Americans, the potential patient population for these medications is enormous. In fact, more than 57 million privately insured adults may qualify for GLP-1 drugs based on clinical criteria.

While their clinical impact can be significant, their growing use has introduced a new financial dynamic into employer health plans.

The Cost Impact on Employer Health Insurance

GLP-1 medications can cost hundreds to more than $1,000 per month per patient, depending on the drug and coverage structure.

As adoption increases, insurers and employers are seeing the financial ripple effects.

Research suggests that expanding GLP-1 coverage could increase employer health insurance premiums by as much as 6–14%, depending on eligibility requirements and patient adherence.

Several factors drive this impact:

1. High Prescription Costs
These medications are among the most expensive commonly prescribed drugs in employer health plans.

2. Large Eligible Population
Because obesity affects more than 40% of U.S. adults, demand for treatment is extremely high.

3. Long-Term Use
Many patients must remain on GLP-1 medications long term to maintain results.

4. Rapid Growth in Utilization
GLP-1 drug claims increased significantly between 2023 and 2025 as awareness and prescriptions surged.

For employers trying to manage healthcare spending, these factors can quickly change the financial outlook of their benefits plan.

The Other Side of the Equation: Health Improvements

While the short-term cost impact is significant, GLP-1 medications may also produce long-term healthcare savings.

Studies analyzing employer health data have shown that patients using GLP-1 medications experienced:

  • Significant reductions in cardiovascular events

  • Lower incidence of certain chronic conditions

  • A slower growth rate in overall medical costs within two years

Healthier employees can mean fewer hospitalizations, lower chronic disease costs, and improved workplace productivity.

For employers, the challenge becomes balancing short-term pharmacy spending with long-term health outcomes.

Why Employers Are Taking Different Approaches

Because of these competing factors, employers across the country are handling GLP-1 coverage in different ways.

Some common strategies include:

  • Covering GLP-1 medications only for diabetes treatment

  • Implementing prior authorization or clinical criteria

  • Requiring participation in lifestyle or weight-management programs

  • Limiting coverage for weight loss indications

Each approach has different cost and employee experience implications.

This is where thoughtful plan design—and experienced guidance—becomes critical.

How Haughn Insurance Helps Employers Navigate This

At Haughn Insurance in Dublin, Ohio, we work closely with employers to navigate emerging healthcare trends like GLP-1 medications and their impact on benefits.

Our team helps clients:

Evaluate plan cost drivers
We analyze pharmacy spend and emerging utilization trends.

Design sustainable health plans
Balancing employee health needs with long-term affordability.

Explore cost-control strategies
Including clinical programs, utilization management, and alternative funding models.

Stay ahead of industry changes
Healthcare and prescription drug trends evolve quickly. We help our clients stay informed and proactive.

The Bottom Line

GLP-1 medications are one of the most significant healthcare developments in recent years. They offer real promise for improving health outcomes—but they also introduce new cost pressures for employer-sponsored health insurance.

Employers that take a proactive, strategic approach to benefits planning will be best positioned to manage these changes.

If your organization is evaluating how GLP-1 medications may impact your health plan, the team at Haughn Insurance in Dublin, Ohio is here to help.

We’re committed to helping employers build smarter benefits strategies that support both employee health and financial sustainability.